Literature DB >> 16055817

Improving 1-year outcome in first-episode psychosis: OPUS trial.

Lone Petersen1, Merete Nordentoft, Pia Jeppesen, Johan Ohlenschaeger, Anne Thorup, Torben Østergaard Christensen, Gertrud Krarup, Jytte Dahlstrøm, Bodil Haastrup, Per Jørgensen.   

Abstract

BACKGROUND: Because early illness course and outcome may affect the long-term outcome of schizophrenia-spectrum disorders, it is especially important to address poor outcome in this early critical period. AIMS: To evaluate whether integrated treatment compared with standard treatment reduced the proportion of patients with poor clinical and social outcome after 1 year.
METHOD: A total of 547 patients with first-episode psychosis were included in the study, 275 randomly assigned to integrated treatment and 272 to standard treatment. Measures assessed psychotic symptoms and social functioning.
RESULTS: There was a significant beneficial effect of integrated treatment v. standard treatment on "any poor outcome". Integrated treatment had a significantly better effect on "any poor outcome" in patients with schizophrenia compared with patients in standard treatment.
CONCLUSIONS: The integrated treatment significantly reduced the proportion of patients with poor clinical and social outcome compared with standard treatment.

Entities:  

Mesh:

Year:  2005        PMID: 16055817     DOI: 10.1192/bjp.187.48.s98

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  36 in total

Review 1.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  The promises and challenges of early intervention in psychotic disorders.

Authors:  Ashok Malla
Journal:  World Psychiatry       Date:  2008-10       Impact factor: 49.548

3.  First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial.

Authors:  Vinod H Srihari; Cenk Tek; Suat Kucukgoncu; Vivek H Phutane; Nicholas J K Breitborde; Jessica Pollard; Banu Ozkan; John Saksa; Barbara C Walsh; Scott W Woods
Journal:  Psychiatr Serv       Date:  2015-02-02       Impact factor: 3.084

Review 4.  Early intervention for psychosis.

Authors:  Max Marshall; John Rathbone
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 5.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 6.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Hanna Bergman; Mariam A Khokhar; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2017-01-06

7.  At issue: Cochrane, early intervention, and mental health reform: analysis, paralysis, or evidence-informed progress?

Authors:  Patrick McGorry
Journal:  Schizophr Bull       Date:  2012-01-12       Impact factor: 9.306

8.  Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study.

Authors:  Xiaofeng Guo; Jinguo Zhai; Zhening Liu; Maosheng Fang; Bo Wang; Chuanyue Wang; Bin Hu; Xueli Sun; Luxian Lv; Zheng Lu; Cui Ma; Xiaolin He; Tiansheng Guo; Shiping Xie; Renrong Wu; Zhimin Xue; Jindong Chen; Elizabeth W Twamley; Hua Jin; Jingping Zhao
Journal:  Arch Gen Psychiatry       Date:  2010-09

Review 9.  The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.

Authors:  Lisa B Dixon; Faith Dickerson; Alan S Bellack; Melanie Bennett; Dwight Dickinson; Richard W Goldberg; Anthony Lehman; Wendy N Tenhula; Christine Calmes; Rebecca M Pasillas; Jason Peer; Julie Kreyenbuhl
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

10.  Ethnic diversity and pathways to care for a first episode of psychosis in Ontario.

Authors:  S Archie; N Akhtar-Danesh; R Norman; A Malla; P Roy; R B Zipursky
Journal:  Schizophr Bull       Date:  2008-11-05       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.